SynthesisHuman vaccines & immunotherapeutics2025
Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis.
Synthesis in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Invasive Pneumococcal Disease in Children: A Retrospective Three-Center Study in Zhejiang Province, China (2010-2024).Infectious diseases and therapy · 2026Article
- Safety of PCV13 with Different Carrier Proteins (CRM197, TT, and TT/DT) - Jiangsu Province, China, 2022-2024.China CDC weekly · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal conjugate vaccines (PCVs) are highly effective against pneumococcal diseases, yet coverage in China remains low. We conducted a systematic review of observational studies published between 2006 and 2024 in mainland China, Hong Kong, and Taiwan to evaluate the effectiveness and impact of PCV7 and PCV13. Twenty-seven studies were identified, of which 17 were included in meta-analyses. PCVs showed strong protection against invasive pneumococcal disease (pooled effectiveness: 88.8%, 95%CI: 80.7-96.8%) and significantly reduced the incidence of community-acquired pneumonia (14.3%, 95%CI: 10.1-18.5%). Vaccine-serotype CAP was reduced by 69.9% (95%CI: 60.0-79.7%), and moderate benefits were observed against severe pneumonia, mortality, and recurrent episodes. Evidence for otitis media remained limited. These findings highlight the substantial health benefits of PCVs in Chinese children and underscore the importance of expanding vaccine utilization to reduce the burden of pneumococcal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.